HDL as a drug and nucleic acid delivery vehicle

Andras G. Lacko, Nirupama A. Sabnis, Bhavani Nagarajan, Walter J. McConathy

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

This review is intended to evaluate the research findings and potential clinical applications of drug transport systems, developed based on the concepts of the structure/function and physiological role(s) of high density lipoprotein type nanoparticles. These macromolecules provide targeted transport of cholesteryl esters (a highly lipophilic payload) in their natural/physiological environment. The ability to accommodate highly water insoluble constituents in their core regions enables High density lipoproteins (HDL) type nanoparticles to effectively transport hydrophobic drugs subsequent to systemic administration. Even though the application of reconstituted HDL in the treatment of a number of diseases is reviewed, the primary focus is on the application of HDL type drug delivery agents in cancer chemotherapy. The use of both native and synthetic HDL as drug delivery agents is compared to evaluate their respective potentials for commercial and clinical development. The current status and future perspectives for HDL type nanoparticles are discussed, including current obstacles and future applications in therapeutics.

Original languageEnglish
Number of pages1
JournalFrontiers in Pharmacology
Volume6
Issue numberOCT
DOIs
StatePublished - 1 Jan 2015

Fingerprint

HDL Lipoproteins
Nucleic Acids
Pharmaceutical Preparations
Nanoparticles
Cholesterol Esters
Antineoplastic Agents
Water
Research

Keywords

  • Drug delivery
  • HDL
  • Lipoproteins
  • Nucleic acid delivery
  • Therapeutics

Cite this

Lacko, Andras G. ; Sabnis, Nirupama A. ; Nagarajan, Bhavani ; McConathy, Walter J. / HDL as a drug and nucleic acid delivery vehicle. In: Frontiers in Pharmacology. 2015 ; Vol. 6, No. OCT.
@article{6eee860c768a47128f4d1952015a0bf3,
title = "HDL as a drug and nucleic acid delivery vehicle",
abstract = "This review is intended to evaluate the research findings and potential clinical applications of drug transport systems, developed based on the concepts of the structure/function and physiological role(s) of high density lipoprotein type nanoparticles. These macromolecules provide targeted transport of cholesteryl esters (a highly lipophilic payload) in their natural/physiological environment. The ability to accommodate highly water insoluble constituents in their core regions enables High density lipoproteins (HDL) type nanoparticles to effectively transport hydrophobic drugs subsequent to systemic administration. Even though the application of reconstituted HDL in the treatment of a number of diseases is reviewed, the primary focus is on the application of HDL type drug delivery agents in cancer chemotherapy. The use of both native and synthetic HDL as drug delivery agents is compared to evaluate their respective potentials for commercial and clinical development. The current status and future perspectives for HDL type nanoparticles are discussed, including current obstacles and future applications in therapeutics.",
keywords = "Drug delivery, HDL, Lipoproteins, Nucleic acid delivery, Therapeutics",
author = "Lacko, {Andras G.} and Sabnis, {Nirupama A.} and Bhavani Nagarajan and McConathy, {Walter J.}",
year = "2015",
month = "1",
day = "1",
doi = "10.3389/fphar.2015.00247",
language = "English",
volume = "6",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S.A.",
number = "OCT",

}

HDL as a drug and nucleic acid delivery vehicle. / Lacko, Andras G.; Sabnis, Nirupama A.; Nagarajan, Bhavani; McConathy, Walter J.

In: Frontiers in Pharmacology, Vol. 6, No. OCT, 01.01.2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - HDL as a drug and nucleic acid delivery vehicle

AU - Lacko, Andras G.

AU - Sabnis, Nirupama A.

AU - Nagarajan, Bhavani

AU - McConathy, Walter J.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - This review is intended to evaluate the research findings and potential clinical applications of drug transport systems, developed based on the concepts of the structure/function and physiological role(s) of high density lipoprotein type nanoparticles. These macromolecules provide targeted transport of cholesteryl esters (a highly lipophilic payload) in their natural/physiological environment. The ability to accommodate highly water insoluble constituents in their core regions enables High density lipoproteins (HDL) type nanoparticles to effectively transport hydrophobic drugs subsequent to systemic administration. Even though the application of reconstituted HDL in the treatment of a number of diseases is reviewed, the primary focus is on the application of HDL type drug delivery agents in cancer chemotherapy. The use of both native and synthetic HDL as drug delivery agents is compared to evaluate their respective potentials for commercial and clinical development. The current status and future perspectives for HDL type nanoparticles are discussed, including current obstacles and future applications in therapeutics.

AB - This review is intended to evaluate the research findings and potential clinical applications of drug transport systems, developed based on the concepts of the structure/function and physiological role(s) of high density lipoprotein type nanoparticles. These macromolecules provide targeted transport of cholesteryl esters (a highly lipophilic payload) in their natural/physiological environment. The ability to accommodate highly water insoluble constituents in their core regions enables High density lipoproteins (HDL) type nanoparticles to effectively transport hydrophobic drugs subsequent to systemic administration. Even though the application of reconstituted HDL in the treatment of a number of diseases is reviewed, the primary focus is on the application of HDL type drug delivery agents in cancer chemotherapy. The use of both native and synthetic HDL as drug delivery agents is compared to evaluate their respective potentials for commercial and clinical development. The current status and future perspectives for HDL type nanoparticles are discussed, including current obstacles and future applications in therapeutics.

KW - Drug delivery

KW - HDL

KW - Lipoproteins

KW - Nucleic acid delivery

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=84949679605&partnerID=8YFLogxK

U2 - 10.3389/fphar.2015.00247

DO - 10.3389/fphar.2015.00247

M3 - Article

AN - SCOPUS:84949679605

VL - 6

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - OCT

ER -